Hederacolchiside A1

Name: Hederacolchiside A1
Brand: MedChemExpress
SKU: HY-N6950
Rating: 4.5 (1 reviews)

Cat. No.: HY-N6950 Purity: 99.69%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro.

For research use only. We do not sell to patients.

Hederacolchiside A1 Chemical Structure

CAS No. : 106577-39-3

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Hederacolchiside A1:

Hederacolchiside A1 (Standard) Get quote

1 Publications Citing Use of MCE Hederacolchiside A1

•Kaohsiung J Med Sci. 2023 Feb 2. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

View All mTOR Isoform Specific Products:

View All Isoforms

mTOR mTORC1 mTORC2

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

Biological Activity
Purity & Documentation
References
Customer Review

Description

Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway^[1]. Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro^[2].

IC₅₀ & Target^[1]

Schistosome

PI3K

mTOR

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	15 μM Compound: 27	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
A549	IC₅₀	4 μM Compound: 27	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	IC₅₀	5.41 μM Compound: HA1	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29958763]
DLD-1	IC₅₀	16 μM Compound: 27	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	4 μM Compound: 27	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
HCT-116	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human HCT116 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human HCT116 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
HCT-116	IC₅₀	8.4 μM Compound: HA1	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
HCT-116	IC₅₀	8.4 μM Compound: HA1	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 27866816]
HCT-116	IC₅₀	8.4 μM Compound: HA1	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
HepG2	IC₅₀	4.21 μM Compound: HA1	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29958763]
HL-60	IC₅₀	2.3 μg/mL Compound: 6	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 10514313]
HL-60	IC₅₀	3.13 μM Compound: HA1	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 29958763]
HT-29	IC₅₀	4.77 μM Compound: HA1	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 29958763]
L02	IC₅₀	7.13 μM Compound: B7	Cytotoxicity against human L02 cells by MTT assay Cytotoxicity against human L02 cells by MTT assay	[PMID: 33964439]
NCI-H460	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human NCI-H460 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
NCI-H460	IC₅₀	3.7 μM Compound: HA1	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
NCI-H460	IC₅₀	3.7 μM Compound: HA1	Growth inhibition of human NCI-H460 cells after 48 hrs by MTT assay Growth inhibition of human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 27866816]
NCI-H460	IC₅₀	3.7 μM Compound: HA1	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
PC-3	IC₅₀	0.85 μM Compound: HA1	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 29958763]
RAW264.7	IC₅₀	0.59 μM Compound: 13	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay	[PMID: 30808589]
SGC-7901	IC₅₀	1.7 μM Compound: HA1	Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
SGC-7901	IC₅₀	1.7 μM Compound: HA1	Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
SK-OV-3	IC₅₀	1.3 μM Compound: HA1	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
SK-OV-3	IC₅₀	3.3 μM Compound: HA1	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
SMMC-7721	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human SMMC7721 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
SMMC-7721	IC₅₀	2.8 μM Compound: HA1	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
SMMC-7721	IC₅₀	2.8 μM Compound: HA1	Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 27866816]
SMMC-7721	IC₅₀	2.8 μM Compound: HA1	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
U-251	IC₅₀	2.2 μM Compound: HA1	Cytotoxicity against human U251 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U251 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
U-251	IC₅₀	2.2 μM Compound: HA1	Growth inhibition of human U251 cells after 48 hrs by MTT assay Growth inhibition of human U251 cells after 48 hrs by MTT assay	[PMID: 27866816]
U-251	IC₅₀	2.2 μM Compound: HA1	Cytotoxicity against human U251 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human U251 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
U-251	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human U251 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human U251 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
U-937	IC₅₀	2.37 μM Compound: HA1	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29958763]

In Vitro

Hederacolchiside A1 reduces the mitochondrial membrane potential and Bcl-2 protein levels, whereas cleaved caspase-3 was higher^[1].
Hederacolchiside A1 effectively inhibits the phosphorylations of phosphatidylinositol 3 kinase (PI3K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

hederacolchiside A1 (3.0, 4.5, and 6.0 mg/kg, ip) can significantly inhibit the weight of tumor in an H22 xenograft model^[1].
Hederacolchiside A1 (3.25, 7.5, and 15.0 mg/kg, ig) can significantly inhibit the weight of tumor in nude mice xenograft tumor models using human breast carcinoma MCF-7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

897.10

Formula

C₄₇H₇₆O₁₆

CAS No.

106577-39-3

Appearance

Solid

Color

White to off-white

SMILES

C[C@]12[C@]3(C([C@@]4([H])[C@](C(O)=O)(CCC(C)(C)C4)CC3)=CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O[C@@]6([H])[C@@H]([C@H]([C@@H](O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)CO)CO6)O)O[C@@]8([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O8)O)O)CC5)C)([H])CC2)C)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (111.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1147 mL	5.5735 mL	11.1470 mL
5 mM	0.2229 mL	1.1147 mL	2.2294 mL
10 mM	0.1115 mL	0.5574 mL	1.1147 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.69%

Select Batch:

Data Sheet (279 KB) SDS (392 KB)

COA (257 KB) HNMR (142 KB) CNMR (135 KB) RP-HPLC (180 KB) MS (74 KB)

Handling Instructions (2659 KB)

References

[1]. Yan-Er Wang, et al. Hederacolchiside A1 suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. Chinese Herbal Medicines.Volume 10, Issue 2, April 2018, Pages 215-222

[2]. Kang N, et al. Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis. Molecules. 2018 Jun 13;23(6). [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1147 mL	5.5735 mL	11.1470 mL	27.8676 mL
	5 mM	0.2229 mL	1.1147 mL	2.2294 mL	5.5735 mL
	10 mM	0.1115 mL	0.5574 mL	1.1147 mL	2.7868 mL
	15 mM	0.0743 mL	0.3716 mL	0.7431 mL	1.8578 mL
	20 mM	0.0557 mL	0.2787 mL	0.5574 mL	1.3934 mL
	25 mM	0.0446 mL	0.2229 mL	0.4459 mL	1.1147 mL
	30 mM	0.0372 mL	0.1858 mL	0.3716 mL	0.9289 mL
	40 mM	0.0279 mL	0.1393 mL	0.2787 mL	0.6967 mL
	50 mM	0.0223 mL	0.1115 mL	0.2229 mL	0.5574 mL
	60 mM	0.0186 mL	0.0929 mL	0.1858 mL	0.4645 mL
	80 mM	0.0139 mL	0.0697 mL	0.1393 mL	0.3483 mL
	100 mM	0.0111 mL	0.0557 mL	0.1115 mL	0.2787 mL